Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study

INTRODUCTION: Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL) and Darunavir (DRV) are commonly prescribed core agents for antiretroviral therapy (ART), and a need exists to compare their clinical effectiveness, as defined by virologic failure risks in real-world settings. METHODS: This obs...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Infect Dis Ther
Autors principals: Mills, Anthony M., Brunet, Laurence, Fusco, Jennifer S., Wohlfeiler, Michael B., Garris, Cindy P., Oglesby, Alan K., Mrus, Joseph M., Lackey, Philip C., Fusco, Gregory P.
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7054577/
https://ncbi.nlm.nih.gov/pubmed/31701370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-019-00274-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars